Literature DB >> 3807892

Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs.

W B Parker, Y C Cheng.   

Abstract

DNA primase (EC 2.7.7.6) produces an RNA oligomer of approximately 10 bases, which is required by DNA polymerase alpha (EC 2.7.7.7) for the initiation of DNA synthesis. We partially purified DNA primase from acute lymphocytic leukemia cells from patients using several chromatography columns. Poly(dT) and poly(dC), but not poly(dA) or poly(dG), were good templates for ribonucleoside triphosphate (rNTP)-dependent DNA synthesis (i.e., DNA primase activity), and they were used in the study of the effect of natural and arabinofuranosyl nucleoside triphosphates on DNA primase activity. The Km for GTP in the poly(dC) primase assay was approximately 175 microM. All noncomplementary natural rNTPs and deoxyribonucleoside triphosphates (dNTPs) inhibited poly(dC) primase activity to a similar extent (Ki values of ATP and CTP were 610 and 517 microM, respectively). 1-beta-D-Arabinofuranosylcytosine 5'-triphosphate (araCTP) and 9-beta-D-arabinofuranosyladenine 5'-triphosphate (araATP) were more potent inhibitors of poly(dC) primase activity than were CTP and ATP (Ki values were approximately 125 microM). araCTP, araATP, CTP, and ATP inhibited DNA primase activity in a manner competitive with GTP. The concentration required to inhibit poly(dC) DNA primase activity by 50% was determined for a number of arabinofuranosyl nucleoside triphosphate analogs, and the relative potency of inhibition of DNA primase activity was as follows: rNTP = dNTP = 5-aza-dCTP less than ara-5-azaCTP = araTTP = araATP = araCTP less than 2-fluoro-araATP = 2'-azido-2'-deoxy araCTP less than 2'-fluoro-araTTP = 2'-fluoro-5-iodo-araCTP = 2'-fluoro-5-methyl-araCTP. In the poly(dT) primase assay ATP did not follow classic Michaelis-Menten kinetics (ATP exhibited positive cooperativity with a Hill coefficient of 2.0). However, this assay was very sensitive to araCTP (apparent Ki of 25 microM). In summary, these experiments suggested that DNA primase is controlled by the levels of ribonucleoside triphosphates, and that the perturbation of these pools by any agent could lead to the inhibition of DNA primase and thereby inhibit DNA synthesis. Furthermore, aranucleoside triphosphate analogs directly inhibited DNA primase, and it is possible that this effect may contribute to the cytotoxicity of these compounds.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3807892

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

Review 1.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Biological effects of a relatively low concentration of 1-beta-D-arabinofuranosylcytosine in K562 cells: alterations of the cell cycle, erythroid-differentiation, and apoptosis.

Authors:  H Yamada; J Horiguchi-Yamada; M Nagai; S Takahara; T Sekikawa; T Kawano; K Itoh; S Fukumi; S Iwase
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

Review 3.  Mechanism and evolution of DNA primases.

Authors:  Robert D Kuchta; Gudrun Stengel
Journal:  Biochim Biophys Acta       Date:  2009-06-21

4.  The Yeast Mitochondrial RNA Polymerase and Transcription Factor Complex Catalyzes Efficient Priming of DNA Synthesis on Single-stranded DNA.

Authors:  Aparna Ramachandran; Divya Nandakumar; Aishwarya P Deshpande; Thomas P Lucas; Ramanagouda R-Bhojappa; Guo-Qing Tang; Kevin Raney; Y Whitney Yin; Smita S Patel
Journal:  J Biol Chem       Date:  2016-06-16       Impact factor: 5.157

5.  Molecular architecture of a multifunctional MCM complex.

Authors:  June Sanchez-Berrondo; Pablo Mesa; Arkaitz Ibarra; Maria I Martínez-Jiménez; Luis Blanco; Juan Méndez; Jasminka Boskovic; Guillermo Montoya
Journal:  Nucleic Acids Res       Date:  2011-10-07       Impact factor: 16.971

Review 6.  Structures to complement the archaeo-eukaryotic primases catalytic cycle description: What's next?

Authors:  Julien Boudet; Jean-Christophe Devillier; Frédéric H-T Allain; Georg Lipps
Journal:  Comput Struct Biotechnol J       Date:  2015-05-02       Impact factor: 7.271

Review 7.  Inhibiting DNA Polymerases as a Therapeutic Intervention against Cancer.

Authors:  Anthony J Berdis
Journal:  Front Mol Biosci       Date:  2017-11-21

8.  Structural Basis for Inhibition of Human Primase by Arabinofuranosyl Nucleoside Analogues Fludarabine and Vidarabine.

Authors:  Sandro Holzer; Neil J Rzechorzek; Isobel R Short; Michael Jenkyn-Bedford; Luca Pellegrini; Mairi L Kilkenny
Journal:  ACS Chem Biol       Date:  2019-09-11       Impact factor: 5.100

9.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

Review 10.  DnaG Primase-A Target for the Development of Novel Antibacterial Agents.

Authors:  Stefan Ilic; Shira Cohen; Meenakshi Singh; Benjamin Tam; Adi Dayan; Barak Akabayov
Journal:  Antibiotics (Basel)       Date:  2018-08-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.